Pular para o conteúdo principal
Ranking Invest

SPPI - Spectrum Pharmaceuticals, Inc.

Segmento: HealthcareSpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.

Análise Ranking Invest

Valuation estimado
-$ 417.15 Mi
Último Balanço Atualizado: 1T2023

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 26.80 Mi

Dívida Líquida

-$ 23.53 Mi

L4T

-$ 65.06 Mi

MM4T

-18648.92%

Indicadores Básicos

ROE

-242.70%

Índices de Previsibilidade

Receita Líquida

G1.14

Lucro

C0.30

Margem

D1.06

Índices de Tendência

Receita Líquida

C5.55

Lucro

B6.65

Margem

F-6.52

Índices de Endividamento

DIV/PAT

-0.88

DIV/L4T

0.36

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.